Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

NCT05765084 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT05765084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05765084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Lead sponsor
University Hospital, Antwerp
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 24, 2023
Completion date
October 31, 2027
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma